DEF 14A: P3 Health Partners Inc. Announces Details for 2024 Annual Stockholder Meeting

P3 Health Partners Inc. will hold its annual stockholder meeting virtually on June 6, 2024, to vote on director elections, auditor ratification, executive compensation, and other matters.

Summary

• P3 Health Partners Inc. is holding its 2024 Annual Meeting of Stockholders on June 6, 2024, at 9:00 a.m. Pacific time, as a virtual meeting.
• Stockholders of record as of April 12, 2024, are entitled to vote.
• The meeting will address the election of three Class III Directors (Jeffrey G. Park, Thomas E. Price, M.D., and Mary Tolan), ratification of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2024, an advisory vote on executive compensation, and an advisory vote on the frequency of future executive compensation votes.
• The Board recommends voting FOR the election of the director nominees, FOR the ratification of BDO USA, P.C., FOR the approval of executive compensation, and ONE YEAR for the frequency of future advisory votes on executive compensation.
• The proxy statement and the 2023 Annual Report are available online, and stockholders can vote by phone, internet, or mail.
• A quorum requires the presence of a majority of the voting power of the Common Stock outstanding on the Record Date.
• The company has nine directors on the board.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for shareholders to make informed decisions.

Positives

• The virtual meeting format provides expanded access, improved communication, and cost savings.
• The Board has an independent Chair and a majority of independent directors.
• The Audit Committee and Compensation and Nominating Committee operate under written charters.
• Stockholders have multiple avenues to vote (phone, internet, mail).
• The company has adopted a Related Person Transaction Policy to ensure fair dealings.

Negatives

• The division of the Board into three classes with staggered three-year terms may delay or prevent a change of management or control.
• Directors may only be removed for cause by the affirmative vote of the holders of a majority of the outstanding voting stock.
• The company is subject to a Tax Receivable Agreement (TRA) that could require substantial payments to P3 Equityholders.
• The TRA could have a material adverse effect on the company's liquidity.

Risks

• The Class D Dispute and the Cash Preference Dispute could impact the allocation of consideration from the Business Combinations.
• The TRA could require substantial payments to P3 Equityholders, potentially impacting the company's liquidity.
• The IRS may challenge the tax benefits claimed under the TRA.
• The company's ability to make payments under the TRA may be limited by restrictions on distributions.
• The company is subject to a standstill restriction from the date of the closing of the March 2023 Private Placement to June 30, 2024 that limits the ownership of the CPF Parties to 49.99% of our Class A common stock and Class V common stock.

Future Outlook

The Board intends to consider the outcome of the advisory votes on executive compensation and its frequency in future compensation decisions.

Management Comments

• Sherif Abdou, M.D., Chief Executive Officer, urges stockholders to promptly vote and submit their proxy.
• The Board believes that separation of the positions of Chair and Chief Executive Officer reinforces the independence of the Board from management.

Industry Context

The document does not provide specific industry context beyond the company's operations in healthcare.

Related Party Transactions

• Chicago Pacific Founders, a P3 Equityholder, made an equity investment in Atrio Holding Company, LLC (Atrio Holdings).
• P3 entered into a Full-Risk capitation agreement with Atrio pursuant to which P3 is delegated to perform services on behalf of Atrios members assigned to P3, including provider network credentialing, patient authorizations and medical management (care management, quality management and utilization management).
• On December 13, 2022, P3 LLC entered into a financing transaction with VGS, consisting of the issuance of the VGS Promissory Note, which provided for funding to us of up to $40.0 million, and the issuance of the VGS Warrants to purchase 429,180 shares of our Class A common stock.
• On March 22, 2024, P3 LLC entered into a financing transaction with VBC Growth SPV 2, LLC (VGS 2) in the form of an unsecured promissory note (the VGS 2 Promissory Note) which provides for funding to us of up to $25.0 million.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will shape the company's direction.
• The outcome of the votes will impact the composition of the Board and the company's approach to executive compensation.
• The TRA could impact the company's financial performance and ability to invest in growth initiatives.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will announce preliminary voting results at the Annual Meeting and report final results in a Current Report on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, Audit Committee, BDO USA, Virtual Meeting, Corporate Governance, P3 Health Partners